Hyperlipoproteinemia Type IIa (Elevated LDL) Medications
Drugs (by generic name) associated with Hyperlipoproteinemia Type IIa (Elevated LDL)
The following drugs and medications are in some way related to, or used in the treatment of Hyperlipoproteinemia Type IIa (Elevated LDL).
This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Hyperlipoproteinemia Type IIa (Elevated LDL) Medications in the Pipeline
MK-0524A (niacin ER and laropiprant)
- June 20, 2008
Merck Provides Update on U.S. Regulatory Status of MK-0524A (ER niacin/laropiprant) and MK-0524B (ER niacin/laropiprant/simvastatin) - April 29, 2008
Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant) - August 29, 2007
Merck Announces FDA Acceptance of NDA for Cordaptive (ER niacin/laropiprant), Formerly Known as MK-0524A, an Investigational Lipid-Modifier






